UroToday

ASCO GU 2026: REJOICE-PanTumor01: A Phase 2 Signal-Seeking Study of Raludotatug Deruxtecan in Patients with Advanced or Metastatic Gynecologic or Genitourinary Tumors

(UroToday.com) The 2026 GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Laurence Albiges discussing REJOICE-PanTumor01, a phase 2 signal-seeking ...
UroToday

ASCO GU 2026: A Phase II Trial of Cabozantinib in Relapsed Refractory Germ Cell Tumors

The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
UroToday

ASCO GU 2026: OPTIMAS: A Phase II Randomized, Decentralized, De-Escalation Trial in Patients with mHSPC Achieving Optimal PSA Response

An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...
UroToday

ASCO GU 2026: Biomarker Analysis from the Phase 2 LITESPARK-013 Study of Two Different Belzutifan Doses in Participants with Advanced Clear Cell RCC

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...
UroToday

ASCO GU 2026: LUNAR: Safety and Efficacy Evaluation of Nadofaragene Firadenovec Instilled into the Renal Pelvis in Subjects with Low-Grade UTUC: A Single-Arm, Open-Label Phase ...

Safety and efficacy evaluation of nadofaragene firadenovec instilled into the renal pelvis in subjects with low-grade upper tract urothelial carcinoma (LG-UTUC): A single-arm, open-label phase 1/2 ...
UroToday

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

These data represent the first published dosimetry data for our investigational formulation of Lu-177 zadavotide guraxetan, with projected mean cumulative renal doses remaining low for a six-cycle ...
UroToday

The Latest Research in Erectile Dysfunction

Development of a Risk Predictive Model for Erectile Dysfunction at 12 Months after COVID-19 Recovery: A Prospective Observational Study - Beyond the Abstract ...
UroToday

ASCO 2025: Phase 1/2 Duravelo-1 Study: Preliminary Results of Nectin-4–targeting Zelenectide Pevedotin (BT8009) plus Pembrolizumab in Previously Untreated, Cisplatin ...

ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.
UroToday

The Latest Bladder Cancer Research

Outcomes of Immune Checkpoint Inhibitor Rechallenge in Advanced Urothelial Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract ...
UroToday

The Latest Research in Male Infertility

Inherited Defects of piRNA Biogenesis Cause Transposon De-Repression, Impaired Spermatogenesis, and Human Male Infertility - Beyond the Abstract ...
UroToday

ASCO 2025: Trials-in-Progress – XALute: Phase 3 Study of Xaluritamig vs Investigator’s Choice of Cabazitaxel or Second Androgen Receptor-Directed Therapy in Post-Taxane ...

ASCO 2025, prostate cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), XALute Study, Xaluritamig, Cabazitaxel, Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy ...
UroToday

The Latest Research in Interstitial Cystitis

Relationship Between the Frequency of Electrocautery of Hunner Lesions and Changes in Bladder Capacity in Patients with Hunner Type Interstitial Cystitis - Beyond the Abstract ...